ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0245

Influence of Forced Vital Capacity Impairment on Treatment Selection and Outcomes in RA-ILD Patients Initiating a Biologic or Targeted-Synthetic DMARD

Bryant England1, Michael George2, Yangyuna Yang1, Punyasha Roul3, Jorge Rojas4, Brian Sauer5, Grant Cannon6, Joshua Baker7, Jeffrey Curtis8 and Ted Mikuls9, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3UNMC, Omaha, NE, 4George E. Wahlen Department of Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, 5Salt Lake City VA/University of Utah, Salt Lake City, UT, 6Salt Lake City VA, Salt Lake city, 7University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, 8Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 9Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

Meeting: ACR Convergence 2022

Keywords: Biologicals, Disease-Modifying Antirheumatic Drugs (Dmards), interstitial lung disease, Pharmacoepidemiology, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: RA – Diagnosis, Manifestations, and Outcomes Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Patients with RA-associated interstitial lung disease (RA-ILD) suffer from substantial morbidity and premature mortality. The optimal use of biologic/tsDMARDs in this population is poorly understood. We evaluated biologic/tsDMARD treatment patterns and outcomes in RA-ILD.

Methods: We identified patients with RA-ILD initiating their first biologic or tsDMARD in the Veterans Health Administration after a diagnosis of ILD between 2006 and 2018. RA-ILD was classified using validated administrative algorithms requiring multiple RA and ILD diagnostic codes (PPV >70%). Pre-treatment initiation FVC values were obtained from pulmonary function test output or extracted from clinical notes using a validated natural language processing program, then categorized as >80%, 60-80%, < 60% predicted, or missing. Patient demographics, health care utilization, comorbidities, and several RA-/ILD-related factors were extracted from EHR and administrative data warehouses. Respiratory-related hospitalizations and vital status were identified during the 3-years after treatment initiation using VA administrative data linked to Medicare and National Death Index data. We evaluated the associations of FVC values with biologic/tsDMARD selection (non-TNFi/JAKi vs. TNFi) and treatment outcomes (respiratory hospitalization, death) in multivariable regression models.

Results: We studied 1,046 RA-ILD patients (mean age 68 years, 92% male), of which 67% initiated a TNFi and 33% a non-TNFi/tsDMARD, including rituximab (n=169), abatacept (n=95), tofacitinib (n=44), and tocilizumab (n=34). Patients with severe FVC impairment (< 60%) more commonly received a non-TNFi/JAKi, although differences were modest and not significant after multivariable adjustment (Table 1). Factors associated with non-TNFi/JAKi selection (referent to TNFi) were female gender, non-White race, more recent calendar years, higher Elixhauser comorbidity scores, more frequent rheumatology and pulmonology visits, and number of prior DMARDs. Baseline use of methotrexate, sulfasalazine, and NSAIDs was associated with TNFi treatment. Within 3-years of treatment initiation, 31% (n=320) had a respiratory-related hospitalization and 24% (n=254) died. RA-ILD patients with a baseline FVC < 60% predicted were at increased risk of respiratory-related hospitalization (HR 1.67 [1.17, 2.36]) and death (HR 1.64 [1.09, 2.45]) compared to those with FVC >80% (Table 2). Additional baseline predictors of respiratory hospitalization and/or death were older age, glucocorticoid use, RF/CCP positivity, elevated ESR/CRP, inhaled corticosteroid use, and baseline home oxygen use. Baseline methotrexate use was associated with a reduced risk of death.

Conclusion: Severe FVC impairment was predictive of respiratory-related hospitalization and mortality after initiating a biologic/tsDMARD but did not strongly influence treatment selection. Despite poor outcomes in patients with severe FVC impairment, providers do not appear to select b/tsDMARDs differently which may reflect the paucity of comparative effectiveness and safety data in RA-ILD.

Supporting image 1

Table 1. Association of forced vital capacity with selection of biologic/tsDMARDs in patients with RA-ILD (n=1,046).

Supporting image 2

Table 2. Association of forced vital capacity with respiratory-related hospitalization and mortality after initiating a biologic/tsDMARD in RA-ILD (n=1,046).


Disclosures: B. England, Boehringer-Ingelheim; M. George, AbbVie, GlaxoSmithKlein(GSK), Chemocentryx; Y. Yang, None; P. Roul, None; J. Rojas, None; B. Sauer, None; G. Cannon, None; J. Baker, Bristol Myers Squibb, Pfizer, CorEvitas LLC, Burns-White, LLC, RediTrex; J. Curtis, Amgen, Bristol-Myers Squibb (BMS), CorEvitas, IlluminationHealth, Janssen, Lilly, Myriad, Novartis, Pfizer, Sanofi, UCB, Aqtual, Bendcare, FASTER, GlaxoSmithKlein (GSK), Labcorp, Scipher, Setpoint, United Rheumatology, AbbVie, ArthritisPower; T. Mikuls, Gilead Sciences, Bristol-Myers Squibb, Horizon, Sanofi, Pfizer Inc.

To cite this abstract in AMA style:

England B, George M, Yang Y, Roul P, Rojas J, Sauer B, Cannon G, Baker J, Curtis J, Mikuls T. Influence of Forced Vital Capacity Impairment on Treatment Selection and Outcomes in RA-ILD Patients Initiating a Biologic or Targeted-Synthetic DMARD [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/influence-of-forced-vital-capacity-impairment-on-treatment-selection-and-outcomes-in-ra-ild-patients-initiating-a-biologic-or-targeted-synthetic-dmard/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/influence-of-forced-vital-capacity-impairment-on-treatment-selection-and-outcomes-in-ra-ild-patients-initiating-a-biologic-or-targeted-synthetic-dmard/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology